TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04817202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (subcutaneous, single dose)
Description: Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, multiple dose)
Description: Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, multiple dose)
Description: Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
Study: NCT00560781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone or Placebo
Description: Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregnenolone or Placebo
Description: Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
Study: NCT04817202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (intravenous, single dose)
Description: Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (subcutaneous, single dose)
Description: Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (intravenous, multiple dose)
Description: Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
Study: NCT03978832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERSERIS
Description: PERSERIS is an extended-release SC injectable suspension administered once-monthly
Study: NCT00706147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimoclomol
Description: Drug: Arimoclomol capsules given three times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo capsules given three times per day
Study: NCT02554994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifactorial intervention
Description: There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS).
Study: NCT01615783

Intervention type: OTHER
Intervention: Subjects with COPD
Description: Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication

Intervention type: OTHER
Intervention: Subjects without COPD
Description: Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
Study: NCT02315092

Intervention type: DEVICE
Intervention: Fluorescence Imaging
Description: Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
Study: NCT01069913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation.
Study: NCT01453166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazilian heart-prevent meal
Description: Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart prevent control meal weekly
Description: received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart prevent control Meal monthly
Description: received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
Study: NCT01110057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GW856553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS856553
Description: GW586553 7.5mg bid
Study: NCT03144167

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of spectroscopic biomarkers of proliferation for six-month survival
Description: Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
Study: NCT00998257

Intervention type: DRUG
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: Patients under daily life treatment with YAZ according to local drug information.
Study: NCT00163644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aereobic plus resisted exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic plus active exercise

Intervention type: OTHER
Group type: OTHER
Intervention: No formal exercise plus phone calls
Study: NCT03577899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg Conbercept Intravitreal Injection
Description: Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.0 mg Conbercept Intravitreal Injection
Description: Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.0 mg Aflibercept Intravitreal Injection
Description: Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
Study: NCT00812955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: Once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: Once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: Once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Once daily for 8 weeks simvastatin capsules 40 mg
Study: NCT03066206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Given PO
Study: NCT04284137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified FE-SaLiR
Description: Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmodified Chinese Medicine Exercise
Description: Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will attend a 60-minute health education program once a week.
Study: NCT02113319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib 50 mg and 20 mg During one year
Study: NCT02234362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine
Description: Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
Study: NCT01263327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18
Description: Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study: NCT03082924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Neither cycle training nor inspiratory muscle training.
Study: NCT00239837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Middle School Success Intervention (MSS)
Description: This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
Study: NCT04659434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~* Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~* R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles
Study: NCT04627116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin
Description: Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin
Description: Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Study: NCT04195100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine Ophthalmic Solution
Description: 1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine Ophthalmic Solution
Description: 1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
Study: NCT00743457

Intervention type: DEVICE
Intervention: Ocular Ultrasound
Description: B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
Study: NCT03255993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 50mg
Description: SPH3127 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 100mg
Description: SPH3127 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 100mg
Description: SPH3127 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to SPH3127 50mg
Description: Placebo matching to SPH3127 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to SPH3127 100mg
Description: Placebo matching to SPH3127 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to SPH3127 100mg
Description: Placebo matching to SPH3127 100mg
Study: NCT00176241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2000-3000mg/m2 IV on days 1 \& 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/m2 IV on days 1 \& 15

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 50-80 cGy on days 1,2,15,16
Study: NCT00718666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose, as intramuscular injection
Study: NCT03082924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrated cycle ergometer
Description: The most common device to perform cycle training is calibrated cycle ergometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold loading device
Description: Threshold loading device is used to perform inspiratory muscle training.
Study: NCT00718666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose, as intramuscular injection
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Study: NCT00835419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
Study: NCT01999166

Intervention type: RADIATION
Intervention: radiography (X-ray)

Intervention type: GENETIC
Intervention: DNA sampling
Study: NCT03060083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)
Description: Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
Study: NCT01896349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amitriptyline
Study: NCT03814330

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Inventory
Description: State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: State-Trait Anxiety Inventory
Description: State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Recovery Score
Description: Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Recovery Score
Description: Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trazodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulpiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulpiride
Study: NCT02697877

Intervention type: DRUG
Intervention: Regadenoson
Study: NCT02990234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular Repair

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No Capsular Repair